ImmunityBio (ImmunityBio) Short-Term Capital Lease Obligation : $6.08 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Short-Term Capital Lease Obligation?

ImmunityBio's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.08 Mil.

ImmunityBio's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($4.36 Mil) to Dec. 2023 ($5.24 Mil) and increased from Dec. 2023 ($5.24 Mil) to Mar. 2024 ($6.08 Mil).

ImmunityBio's annual Short-Term Capital Lease Obligation declined from Dec. 2021 ($3.01 Mil) to Dec. 2022 ($2.65 Mil) but then increased from Dec. 2022 ($2.65 Mil) to Dec. 2023 ($5.24 Mil).

ImmunityBio Short-Term Capital Lease Obligation Historical Data

The historical data trend for ImmunityBio's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Short-Term Capital Lease Obligation Chart

ImmunityBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

5.02

3.01

2.65

5.24

ImmunityBio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial													2.84	5.98	4.36	5.24	6.08

ImmunityBio Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

ImmunityBio Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio (ImmunityBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

26CA:Germany

Address

3530 John Hopkins Court, San Diego, CA, USA, 92121

Website

https://www.immunitybio.com

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

Executives

Patrick Soon-shiong	director, 10 percent owner, officer: See remarks	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk	director	C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark	director	C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer	officer: Chief Accounting Officer	4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock	officer: Chief Executive Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs	officer: Chief Financial Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll	director